Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits

被引：44

作者：

Capilla, J

Yustes, C

Mayayo, E

Fernández, B

Ortoneda, M

Pastor, FJ

Guarro, J

机构：

[1] Univ Rovira & Virgili, Fac Med, Unitat Microbiol, E-43201 Reus, Spain

[2] Univ Rovira & Virgili, Fac Med, Unitat Anat Patol, E-43201 Reus, Spain

[3] Hosp Univ Terragona Joan XXIII, Serv Patol, Tarragona, Spain

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2003年 / 47卷 / 06期

关键词：

D O I：

10.1128/AAC.47.6.1948-1951.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

There are no effective therapeutics for treating invasive Scedosporium prolificans infections. Doses of 15, 25, and 50 mg/kg of body weight/day for the new triazole albaconazole (ABC) were evaluated in an immunocompetent rabbit model of systemic infection with this mold. Treatments were begun 1 day after challenge and given for 10 days. ABC at any dose was more effective than amphotericin B (AMB) at 0.8 mg/kg/day at clearing S. prolificans from tissue (P < 0.007). The percentages of survival at 25 mg of ABC/kg/day were similar to those obtained with AMB. Rabbits showed 100% survival when they were treated with 50 mg of ABC per kg (P < 0.0001 versus control group), and only this dosage was able to reduce tissue burden significantly in the five organs studied, i.e., spleen, kidneys, liver, lungs, and brain.

引用

页码：1948 / 1951

页数：4

共 23 条

[1] New azole antifungals.: 3.: Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones
Bartroli, J
Turmo, E
Algueró, M
Boncompte, E
Vericat, ML
Conte, L
Ramis, J
Merlos, M
García-Rafanell, J
Forn, J
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (11) : 1869 - 1882
[2] Deep infections caused by Scedosporium prolificans - A report on 16 cases in Spain and a review of the literature
Berenguer, J
RodriguezTudela, JL
Richard, C
Alvarez, M
Sanz, MA
Gaztelurrutia, L
Ayats, J
MartinezSuarez, JV
[J]. MEDICINE, 1997, 76 (04) : 256 - 265
[3] CANO J, 1992, J MED VET MYCOL, V30, P413
[4] In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi
Capilla, J
Ortoneda, M
Pastor, FJ
Guarro, J
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) : 2635 - 2637
[5] In vitro activities of four novel triazoles against Scedosporium spp.
Carrillo, AJ
Guarro, J
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) : 2151 - 2153
[6] Development of a murine model of cerebral aspergillosis
Chiller, TM
Luque, JC
Sobel, RA
Farrokhshad, K
Clemons, KV
Stevens, DA
[J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (04) : 574 - 577
[7] Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum
Cuenca-Estrella, M
Ruiz-Díez, B
Martínez-Suárez, JV
Monzón, A
Rodríguez-Tudela, JL
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) : 149 - 151
[8] DEHOOG GS, 1994, MYCOSES, V37, P71, DOI 10.1111/j.1439-0507.1994.tb00780.x
[9] In vitro activities of 10 antifungal drugs against 508 dermatophyte strains
Fernández-Torres, B
Carrillo, AJ
Martín, E
Del Palacio, A
Moore, MK
Valverde, A
Serrano, M
Guarro, J
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) : 2524 - 2528
[10] Gosbell I. B., 1999, Clinical Microbiology and Infection, V5, P672, DOI 10.1111/j.1469-0691.1999.tb00513.x

← 1 2 3 →